Patents by Inventor Brian Ishida

Brian Ishida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Determining Risk of a Cardiovascular Occlusive Event
    Publication number: 20140308683
    Abstract: The present disclosure provides methods for assessing risk of a cardiovascular occlusive event in an individual. The methods find use in diagnostic and prognostic applications. The present disclosure provides a method for measuring the level of pre?-1 high density lipoprotein in a biological sample; and also provides kits for use in carrying out the method.
    Type: Application
    Filed: March 7, 2012
    Publication date: October 16, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: John P. Kane, Brian Ishida, Mary Malloy
  • Treatment for dark adaptation
    Publication number: 20050282750
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Application
    Filed: February 10, 2005
    Publication date: December 22, 2005
    Inventors: Daniel Schwartz, Keith Duncan, Kathy Bailey, John Kane, Brian Ishida
  • Treatment for age-related macular degeneration (AMD)
    Publication number: 20030162758
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 28, 2003
    Inventors: Daniel M. Schwartz, Keith Duncan, Kathy Bailey, John Kane, Brian Ishida